Login Register Cart 0
Generic placeholder image

Clinical Cancer Drugs

Editor-in-Chief

ISSN (Print): 2212-697X
ISSN (Online): 2212-6988

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Targeting Breast Cancer Stem Cells (BCSCs) with Liposomal Formulations

Author(s): Sumayah Al-Mahmood*

Volume 6, Issue 1, 2019

Page: [3 - 7] Pages: 5

DOI: 10.2174/2212697X06666190318150757

Abstract

Breast cancer stem cells (BCSCs) are a small proportion of cells that may be responsible for improving the resistance of cancer cells to the treatment and metastasis of breast cancer (MBC). Nanovehicles such as liposomes are extensively explored for diagnosis, treatment, and imaging of cancer. Targeted therapy with nanoparticles can be used to overcome the chemoresistance problem of cancer stem cells. Liposomes are lipid bilayer nanocarriers that have the ability to inhibit Pglycoprotein to overcome multidrug resistance that makes liposome ideal choice for using in BCSCs therapy. The main objective of this review is to describe novel liposomal formulations that are used in targeting BCSCs, which help in improving breast cancer treatment.

Keywords: Breast cancer stem cells, liposomes, drug delivery, nanotechnology, breast cancer, targeted treatment.

Graphical Abstract

[1]
Jung YC, Han S, Hua L, et al. Kazinol-E is a specific inhibitor of ERK that suppresses the enrichment of a breast cancer stem-like cell population. Biochem Biophys Res Commun 2016; 470(2): 294-9.
[2]
Zuo ZQ, Chen KG, Yu XY, et al. Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition. Biomaterials 2016; 82: 48-59.
[3]
Hong IS, Jang GB, Lee HY, Nam JS. Targeting cancer stem cells by using the nanoparticles. Int J Nanomedicine 2015; 10: 251-60.
[4]
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 2003; 100(7): 3983-8.Available from:. https://www.pnas.org/content/100/7/3983
[5]
Hu J, Li G, Zhang P, Zhuang X, Hu GA. CD44v+ subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity. Cell Death Amp Dis 2017; 8e2679Available from:.
[http://dx.doi.org/10.1038/cddis.2017.72]
[6]
Pal D, Kolluru V, Chandrasekaran B, et al. Targeting aberrant expression of Notch-1 in ALDH+ cancer stem cells in breast cancer. Mol Carcinog 2017; 56(3): 1127-36.Available from:.
[http://dx.doi.org/10.1002/ mc.22579]
[7]
Toledo-Guzmán ME, Bigoni-Ordóñez GD, Hernández MI, Ortiz-Sánchez E. Cancer stem cell impact on clinical oncology. World J Stem Cells 2018; 10(12): 183-95.
[8]
Smita Bonde SN. Advances in liposomal drug delivery system: Fascinating types and potential applications. Int J Appl Pharm 2017; 9(3): 1-7.
[9]
Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther 2019; 34(1): 1-8.
[10]
Gener P, Rafael DF, Fernández Y, et al. SSJ. Cancer stem cells and personalized cancer nanomedicine. Nanomedicine 2016; 11(3): 307-20.
[11]
Kotiyal S, Bhattacharya S. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 2014; 453(1): 112-6.
[12]
Burke Andrew R, Singh Ravi N, Carroll DL, Torti FM, Torti SV. Targeting cancer stem cells with nanoparticle-enabled therapies. J Mol Biomark Diagn [Internet] 2012.Available from:. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875221/#__ffn_sectitle
[13]
Li SY, Sun R, Wang HX, et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J Control Release 2015; 205: 7-14.
[14]
Krishnamurthy S, Ke X, Yang YY. Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells. Nanomedicine 2015; 10(1): 143-60.
[15]
Minko T, Dharap SS, Pakunlu RIWY. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 2004; 5(4): 389-406.
[16]
Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011; 153(3): 198-205.
[17]
Suri SS, Fenniri HSB, Ravichandran R. Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2007; 5(1-4): 17-33.
[18]
Anitha P, Bhargavi J, Sravani G, Aruna B, Ramkanth S. Recent progress of dendrimers in drug delivery for cancer therapy. Int J Appl Pharm 2018; 10(5): 34-42.
[19]
Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol 2014; 5: 1-22.
[20]
Minko T, Pakunlu RI, Wang Y, Khandare JJSM. New generation of liposomal drugs for cancer. Anticancer Agents Med Chem 2006; 6(6): 537-52.
[21]
Nounou MI, Elamrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies supplementary issue: Targeted therapies in breast cancer treatment. Breast Cancer Basic Clin Res 2015; 9: 17-34.
[22]
Liu Y, Lu WL, Guo J, et al. A potential target associated with both cancer and cancer stem cells: A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 2008; 129(1): 18-25.
[23]
Guo J, Zhou J, Ying X, et al. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. 2010; 13(2): 136-51.
[24]
Liao D, Liu Z, Wrasidlo W, et al. Synthetic enzyme inhibitor: A novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomed Nanotechnol Biol Med 2011; 7(6): 665-73.
[25]
Liao D, Liu Z, Wrasidlo WJ, et al. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Res 2011; 71(17): 5688-96.
[26]
Zhang L, Yao HJ, Yu Y, et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012; 33(2): 565-82.
[27]
Sun Y, Kim HS, Saw PE, Jon S, Moon WK. Targeted therapy for breast cancer stem cells by liposomal delivery of siRNA against Fibronectin EDB. Adv Healthc Mater 2015; 4(11): 1675-80.
[28]
Ahmad A, Mondal SK, Mukhopadhyay D, Banerjee R, Alkharfy KM. Development of liposomal formulation for delivering anticancer drug to breast cancer stem-cell-like cells and its pharmacokinetics in an animal model. Mol Pharm 2016; 13(3): 1081-8.

Rights & Permissions Print Cite
Article Metrics
84
4
1
1
© 2024 Bentham Science Publishers | Privacy Policy